Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Oct
27
Today In Oncology
Omega-3 EPA Linked to Longer Survival After Surgery for Colorectal Cancer Liver Metastases
High-Risk Melanoma Personalized mRNA Vaccine Plus Immunotherapy Reduces Risk of Recurrence After Surgery
FDA Approves Talazoparib With Enzalutamide for Certain Metastatic HRR-Mutated Prostate Cancers
GLP-1 RA Use Lower Among Adults With Both Diabetes and a History of Cancer
Triplet Therapy With Abiraterone Improves OS Long-Term in Metastatic Castration-Sensitive Prostate Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo